drugset / Trial / NCT05933525
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
Phase 2
Completed
63 enrolled
Immuron Ltd.
Naval Medical Research Center · collabUnited States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a randomized, double-blind, placebo-controlled study to investigate a single daily dose of Travelan® protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli (ETEC) strain H10407.
Timeline
- Start
- 2023-05-29
- Primary completion
- 2024-07-01
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Travelan | Unknown | 1200 mg | Oral |